The acquired intellectual property portfolio focuses on age-related diseases and cognitive health, areas that align with Universe Pharmaceuticals’ current trajectory in elderly healthcare. By integrating these assets, the firm aims to catalyze new research and development pipelines while exploring co-development and licensing opportunities to bolster its commercial reach. Management stated that these patents are inherently complementary to their existing pharmaceutical business model. The transaction is slated to close in the third quarter, pending customary conditions.
Universe Pharmaceuticals Targets Patent Portfolio in $10.8M Acquisition
Universe Pharmaceuticals has finalized an agreement to acquire Best Praise International Limited for $10.8 million in stock. The move secures control over five Chinese patents, marking a strategic pivot for the company as it seeks to expand its footprint in neurodegenerative research and advanced drug delivery systems.
Comments (0)
No comments yet. Be the first!